Payment overview · 2025
General Payments
$328.82
20 reported records · 6 companies
Healthcare provider profile · identity verified
Lance Shinn, DO
Allopathic & Osteopathic Physicians|Internal Medicine · DANIELS, WV · NPI 1316468192
Verified facts
What the public records show
CMS Open Payments records show Lance Shinn, DO received $328.82 in general payments during 2025 across 20 reported records.
Novo Nordisk Inc accounted for 42.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Trelegy Ellipta, Wegovy.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $138.00 | 42.0% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $96.51 | 29.4% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.59 | 10.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.57 | 8.1% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $17.90 | 5.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.25 | 4.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $328.82 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $96.51 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $82.22 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.59 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.61 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $26.57 | 2 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $17.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $15.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 268 | 81 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 73 |
| Lisinopril | Lisinopril | 238 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 206 | 61 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 156 | 45 |
| Meloxicam | Meloxicam | 149 | 54 |
| Gabapentin | Gabapentin | 143 | 41 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 140 | 23 |
| Omeprazole | Omeprazole | 138 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 137 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 133 | 42 |
| Furosemide | Furosemide | 124 | 46 |
| Tramadol Hcl | Tramadol Hcl | 123 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 40 |
| Trazodone Hcl | Trazodone Hcl | 117 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 115 | 39 |
| Montelukast Sodium | Montelukast Sodium | 107 | 35 |
| Metformin Hcl Er | Metformin Hcl | 104 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 97 | 32 |
| Ozempic | Semaglutide | 95 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 31 |
| Prednisone | Prednisone | 94 | 70 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 30 |
| Alprazolam | Alprazolam | 87 | 18 |
| Clonazepam | Clonazepam | 79 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 27 |
| Buspirone Hcl | Buspirone Hcl | 76 | 31 |
| Potassium Chloride | Potassium Chloride | 75 | 31 |
| Ondansetron Odt | Ondansetron | 72 | 22 |
| Metformin Hcl | Metformin Hcl | 71 | 24 |
| Eliquis | Apixaban | 69 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 16 |
| Lorazepam | Lorazepam | 59 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 58 | 16 |
| Carvedilol | Carvedilol | 55 | 15 |
| Allopurinol | Allopurinol | 52 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 17 |
| Famotidine | Famotidine | 48 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 11 |
| Simvastatin | Simvastatin | 46 | 16 |
| Ibuprofen | Ibuprofen | 44 | 13 |
| Sertraline Hcl | Sertraline Hcl | 44 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 12 |
| Mounjaro | Tirzepatide | 37 | 13 |
| Atenolol | Atenolol | 36 | 11 |
| Azithromycin | Azithromycin | 36 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Finasteride | Finasteride | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 31 | 16 |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Glimepiride | Glimepiride | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 16 |
| Amoxicillin | Amoxicillin | 26 | 22 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Ezetimibe | Ezetimibe | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Nystatin | Nystatin | 24 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 19 |
| Jardiance | Empagliflozin | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Wegovy | Semaglutide | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Hydrocodone-Ibuprofen | Hydrocodone/Ibuprofen | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $328.82 · 20 records | Novo Nordisk Inc | General - Therapies, Ozempic, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, Wegovy, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error